Coloplast A/S

CPSE:COLO B Stock Report

Market Cap: DKK 86.3b

Coloplast Future Growth

Future criteria checks 5/6

Coloplast is forecast to grow earnings and revenue by 25.4% and 6.4% per annum respectively. EPS is expected to grow by 24.7% per annum. Return on equity is forecast to be 35.9% in 3 years.

Key information

25.4%

Earnings growth rate

24.68%

EPS growth rate

Medical Equipment earnings growth15.3%
Revenue growth rate6.4%
Future return on equity35.89%
Analyst coverage

Good

Last updated01 Jun 2026

Recent future growth updates

Analysis Article • May 15

Coloplast A/S Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...
Analysis Article • Aug 22

Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

It's been a good week for Coloplast A/S ( CPH:COLO B ) shareholders, because the company has just released its latest...

Recent updates

Narrative Update • Jun 02

COLO B: New CEO And Lower P/E Will Support Future Multiple Re Rating

The updated analyst price target for Coloplast moves from DKK 500.15 to DKK 461.90, as analysts factor in slightly firmer revenue growth assumptions, a small change in the discount rate, and a lower future P/E multiple, while recent research highlights both reduced targets and one new Buy initiation after the share selloff. Analyst Commentary Recent Street research on Coloplast reflects a mix of optimism and caution, with several firms adjusting price targets and ratings following the share selloff.
Analysis Article • May 20

Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings

Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...
Analysis Article • May 15

Coloplast A/S Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Last week saw the newest half-year earnings release from Coloplast A/S ( CPH:COLO B ), an important milestone in the...
Narrative Update • May 10

COLO B: New CEO And Reset P/E Will Support Future Multiple Re Rating

The analyst price target on Coloplast has been reduced from DKK 551.68 to DKK 500.15, as analysts incorporate a series of recent target cuts and mixed ratings while adjusting assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research on Coloplast has centered on a series of target cuts and rating changes that feed directly into the revised average price target.
Narrative Update • Apr 24

COLO B: New CEO Appointment Will Underpin Future Multiple Re Rating Potential

Coloplast's analyst price target has been nudged lower to about DKK 552 from roughly DKK 561, reflecting recent cuts to DKK-based targets by several banks as analysts factor in a slightly higher discount rate, a modestly adjusted future P/E assumption and only small tweaks to long term growth and margin expectations. Analyst Commentary Recent Street research around Coloplast has centered on recalibrated price targets and rating changes as analysts reassess what they are willing to pay for the company, given updated discount rates and P/E assumptions.
Narrative Update • Apr 09

COLO B: New CEO Appointment Will Support Future Re Rating Potential

The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.
Narrative Update • Mar 26

COLO B: New CEO Appointment And Reset P/E Will Support Future Re Rating

Coloplast's analyst fair value target has been trimmed from DKK 579.78 to DKK 567.16, as analysts factor in slightly lower long term growth, modestly softer margin assumptions and small adjustments to future P/E expectations following a mix of recent target cuts and one upgrade. Analyst Commentary Recent research on Coloplast has been mixed, with several target cuts alongside one upgrade.
Narrative Update • Mar 11

COLO B: Reset P/E And New Leadership Will Support Future Re Rating

The updated analyst price target for Coloplast has been trimmed by around DKK 9 to reflect lower Street targets. This includes cuts to DKK 504 at Deutsche Bank and reductions at RBC Capital, JPMorgan and Berenberg, as analysts factor in slightly higher discount rates, modestly softer margin assumptions and a lower future P/E multiple.
Narrative Update • Feb 25

COLO B: Reset P/E And Dividend Will Support Future Re Rating

Analysts have trimmed their DKK price targets on Coloplast, reflected in a lower fair value estimate from DKK 615 to DKK 588, as they factor in slightly more cautious assumptions on growth, margins and future P/E multiples following recent target reductions from several research houses. Analyst Commentary Bullish Takeaways Bullish analysts still see room for upside from current levels, even with reduced DKK price targets.
Narrative Update • Feb 10

COLO B: Reset P/E And Dividend Will Support Future Upside

Analysts have trimmed their fair value estimate for Coloplast from DKK 678.22 to DKK 615.06, reflecting recent price target cuts and updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. Analyst Commentary Recent Street research on Coloplast has focused on recalibrating expectations rather than fundamentally changing the story.
Analysis Article • Jan 25

Coloplast A/S' (CPH:COLO B) P/E Is On The Mark

Coloplast A/S' ( CPH:COLO B ) price-to-earnings (or "P/E") ratio of 33.6x might make it look like a strong sell right...
Narrative Update • Jan 24

COLO B: Dividend Reliability And Premium P/E Will Support Future Upside

Analysts have lowered their Coloplast price targets by DKK 10, to a range of DKK 535 to DKK 640, reflecting slightly lower fair value assumptions, modestly softer revenue growth expectations, and a marginally reduced future P/E multiple. Analyst Commentary Recent research updates on Coloplast point to a tighter valuation range, with price targets now clustered between DKK 535 and DKK 640.
Narrative Update • Jan 09

COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside

Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.
Narrative Update • Dec 13

COLO B: Sustained Margin Strength Will Support Upside As Dividend Payouts Increase

Analysts have nudged our Coloplast fair value estimate slightly higher to about DKK 689 per share from roughly DKK 689 previously, reflecting a modest uptick in long term multiple assumptions even as recent Street price target revisions have moved in mixed directions. Analyst Commentary Recent Street actions on Coloplast highlight a divided view on near term upside versus longer term execution and growth.
Analysis Article • Dec 04

Coloplast (CPH:COLO B) Is Increasing Its Dividend To DKK18.00

Coloplast A/S ( CPH:COLO B ) has announced that it will be increasing its dividend from last year's comparable payment...
Narrative Update • Nov 29

COLO B: Sustained Margin Strength Will Support Upside Amid Market Challenges

Coloplast’s analyst fair value estimate was revised slightly upward to DKK 688.67 from DKK 685.39. Analysts weighed recent price target changes along with minor adjustments to growth expectations and profit margins.
Analysis Article • Nov 20

Coloplast (CPH:COLO B) Will Pay A Larger Dividend Than Last Year At DKK18.00

Coloplast A/S ( CPH:COLO B ) will increase its dividend from last year's comparable payment on the 9th of December to...
Narrative Update • Nov 14

COLO B: Future Execution In Core Markets Will Drive Share Price Momentum

The analyst consensus price target for Coloplast has modestly decreased. Updated projections reflect cautious sentiment from analysts, who cite modest adjustments to growth and profitability expectations.
Narrative Update • Oct 31

COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance

Coloplast’s analyst price target was reduced slightly from DKK 691.83 to DKK 686.00, as analysts cite modestly lower revenue growth expectations and recent target decreases across several major firms. Analyst Commentary Recent commentary from market analysts highlights a balanced perspective on Coloplast’s outlook, with both raised and lowered price targets reflecting shifting sentiment in key performance areas.
Narrative Update • Oct 17

Chronic Care Focus And Emerging Markets Will Redefine Healthcare

Coloplast's analyst price target has been reduced by nearly DKK 10 to DKK 691.83. Analysts cite mixed recent revisions in target prices, reflecting a balanced outlook amid evolving growth and margin expectations.
Narrative Update • Oct 03

Chronic Care Focus And Emerging Markets Will Redefine Healthcare

Coloplast's analyst price target has been revised downward from DKK 716 to DKK 701. Analysts have adjusted their expectations in response to a series of recent target reductions following tempered growth and margin forecasts.
Narrative Update • Aug 30

Chronic Care Focus And Emerging Markets Will Redefine Healthcare

Coloplast’s consensus price target was modestly reduced to DKK718.06 as analysts weighed concerns about slowing revenue growth and margin pressure against stable demand in key product portfolios and longer-term benefits from innovation and expansion. Analyst Commentary Bearish analysts cite concerns over slowing revenue growth and margin pressure, particularly in core European markets.
Analysis Article • Aug 22

Coloplast A/S Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

It's been a good week for Coloplast A/S ( CPH:COLO B ) shareholders, because the company has just released its latest...
User avatar
New Narrative • Nov 07

Operational Efficiencies And Innovations In Urology And Wound Care Propel Future Growth

Improved operational efficiency and strategic expansions are expected to enhance net margins and earnings over the long term.

Earnings and Revenue Growth Forecasts

CPSE:COLO B - Analysts future estimates and past financials data (DKK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202832,7096,4986,0407,50919
9/30/202730,7125,9615,5376,94420
9/30/202628,7373,1545,5886,41219
3/31/202628,0452,1065,9237,595N/A
12/31/202527,8913,9895,3386,871N/A
9/30/202527,8743,6365,2186,645N/A
6/30/202527,8674,0754,9486,428N/A
3/31/202527,7944,5444,8736,287N/A
12/31/202427,4504,8841,6072,985N/A
9/30/202427,0305,0521,4202,766N/A
6/30/202426,3034,9671,3132,599N/A
3/31/202425,5264,9651,0532,278N/A
12/31/202325,0014,8684,2855,527N/A
9/30/202324,5004,7832,9854,226N/A
6/30/202324,3334,7843,2264,485N/A
3/31/202324,0744,8013,6634,894N/A
12/31/202223,5154,6263,2464,455N/A
9/30/202222,5794,7063,9645,099N/A
6/30/202221,6204,7813,8944,913N/A
3/31/202220,6064,7463,7354,712N/A
12/31/202119,8574,8964,2725,209N/A
9/30/202119,4264,8253,3245,290N/A
6/30/202118,9164,5613,1025,023N/A
3/31/202118,5004,3043,1625,077N/A
12/31/202018,5704,2413,0034,941N/A
9/30/202018,5444,1973,8284,759N/A
6/30/202018,5723,9493,8764,842N/A
3/31/202018,7524,0203,8724,764N/A
12/31/201918,3303,974N/A4,615N/A
9/30/201917,9393,873N/A4,357N/A
6/30/201917,5554,119N/A4,161N/A
3/31/201917,1813,999N/A4,177N/A
12/31/201816,8153,896N/A4,126N/A
9/30/201816,4493,845N/A4,361N/A
6/30/201816,1953,816N/A4,370N/A
3/31/201815,8823,778N/A4,111N/A
12/31/201715,7283,791N/A4,004N/A
9/30/201715,5283,797N/A3,251N/A
6/30/201715,2873,211N/A2,994N/A
3/31/201715,0613,279N/A2,492N/A
12/31/201614,7803,264N/A2,653N/A
9/30/201614,6813,143N/A3,028N/A
6/30/201614,5631,297N/A3,081N/A
3/31/201614,4171,028N/A3,568N/A
12/31/201514,264927N/A3,320N/A
9/30/201513,909899N/A3,337N/A
6/30/201513,5023,162N/A3,119N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLO B's forecast earnings growth (25.4% per year) is above the savings rate (2%).

Earnings vs Market: COLO B's earnings (25.4% per year) are forecast to grow faster than the Danish market (9% per year).

High Growth Earnings: COLO B's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: COLO B's revenue (6.4% per year) is forecast to grow faster than the Danish market (3.9% per year).

High Growth Revenue: COLO B's revenue (6.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: COLO B's Return on Equity is forecast to be high in 3 years time (35.9%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 16:50
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coloplast A/S is covered by 40 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Hassan Al-WakeelBarclays
Alexander KlebanBarclays